Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.
'While salary increments are moderating compared to last year, not all functions are moving at the same pace.'
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
Indian pharmaceutical companies are strategically increasing investments in the US market, focusing on specialty drugs, complex generics, respiratory products, and local manufacturing, despite a nearly 10 per cent fall in exports to the US in FY26 due to pricing pressure and competition in traditional generics.
Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.
There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies. Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based Organon & Co as both a "happy" and "bit anxious" moment, acknowledging the significant debt required to fund the large transaction.
Indian benchmark indices Sensex and Nifty rebounded in early trade after three days of decline, driven by a rally in Sun Pharma following its USD 11.75 billion acquisition of US-based Organon & Co, alongside a positive trend in global equity markets.
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
Indian benchmark indices Sensex and Nifty experienced a significant decline in early trade, driven by renewed tensions between the US and Iran and a subsequent spike in global crude oil prices, creating uncertainty in the market. Track Sensex, Nifty on July 8.
Indian stock markets witnessed a significant rally, with the Sensex climbing 964.58 points and the Nifty reaching 24,330, driven by strong buying in blue-chip stocks, particularly in the IT and banking sectors, amidst optimism over Q1 earnings and a shift towards large-cap investments.
Indian benchmark indices Sensex and Nifty rebounded in early trade on Thursday, recovering from a sharp fall in the previous session, driven by foreign fund inflows and buying in key blue-chip stocks. Track Sensex, Nifty on July 9, 2026.
Indian benchmark indices Sensex and Nifty rallied in early trade, primarily driven by strong buying in IT stocks after Tech Mahindra reported a significant 28.4 per cent rise in its consolidated net profit for the June quarter.
Disappointed with past experience, domestic majors even skip giving any memorandum.
Indian benchmark indices Sensex and Nifty experienced a downturn in early trade, primarily influenced by a dip in HDFC Bank shares, persistent outflows from foreign funds, and escalating geopolitical tensions between the US and Iran. Track Sensex, Nifty performance.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
Indian benchmark indices Sensex and Nifty continued their upward trend for a second consecutive day, with the Sensex gaining over 800 points, driven by strong performances from heavyweights like Reliance Industries, ICICI Bank, and HDFC Bank, alongside positive cues from easing crude oil prices and robust IT sector earnings.
Companies are already diversifying sourcing, raising prices, and reworking operating models as the disruption drags on.
A big slice of the employment pie in the pharma industry is for graduates, who can be easily absorbed at the entry-level.
Indian stock markets, including the Sensex and Nifty, rebounded significantly, driven by a decline in crude oil prices and positive global cues stemming from hopes of diplomatic progress in US-Iran negotiations.
Indian benchmark equity indices, Sensex and Nifty, extended their winning streak for a third consecutive day, driven by a rally in IT stocks and global cues suggesting a more accommodative monetary policy after softer-than-expected US jobs data.
The Indian banking sector is projected to experience a steady 9-13 per cent industrial credit growth in the first half of 2026, driven by capital expenditure, infrastructure development, and sectoral demand recovery, according to a Ficci-IBA survey.
'ISRO is planning to build a Bharatiya Antariksh Station by 2030. So, our goal is to create a vehicle that can supply modules to the Bharatiya Antariksh Station and bring the products back.'
The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.
India's pharmaceutical exports have shown robust growth, reaching over USD 28 billion, despite global economic challenges. The sector is projected to reach USD 130 billion by 2030.
Notwithstanding the fact that the country's pharmaceutical (pharma) pricing regulator has allowed a 12 per cent price increase for medicines listed under the National List of Essential Medicines (NLEM) in 2023, analysts and industry insiders predict that the overall domestic pharma industry will only witness a price hike of 5-6 per cent. This is attributed to higher competitive intensity in the market. Krishnakumar V, executive director and chief operating officer (CEO) of Eris Lifesciences, a domestic-focused pharma company, noted that the NLEM segment experienced growth suppression of around 150 basis points due to price reductions during the January to July period this year.
The launch highlights the growing maturity of India's nuclear medicine ecosystem.
A strong third-quarter (October-December/Q3) performance for 2025-26 (FY26) has helped the stock of India's largest listed pharmaceutical (pharma) company, Sun Pharmaceutical Industries, gain about 7 per cent since the start of February.
Hyderabad-based SETL, a precision engineering company, has acquired a 51% majority stake in GScale Energy Private Limited, an AI Datacenter Engineering infrastructure specialist. This strategic move involves an initial investment of Rs 190 crore, with a total commitment of Rs 500 crore, marking SETL's expansion into the rapidly growing AI Datacenter sector and leveraging its expertise from pharmaceutical and chemical industries.
For decades, multinational pharmaceutical companies and Indian drugmakers worked in ways that supported each other: MNCs brought innovation and brands, while Indian companies built scale through generics and cost efficiency. There was an important overlap - generic drugs - but this is shrinking fast. And the consequences are reshaping India's gigantic pharmaceutical market.
The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.The US pharma industry has expressed concern over deteriorating intellectual property environment in India, alleging that patent rights in the country are unreasonably denied.
Indian benchmark stock indices Sensex and Nifty rebounded nearly 1 per cent, snapping a three-day decline, driven by rallies in Reliance Industries and Sun Pharma, alongside positive global market trends and easing geopolitical tensions.
Indian benchmark indices Sensex and Nifty experienced a significant slump in early trade, mirroring a sharp decline in global equities and a fresh spike in crude oil prices, exacerbated by simmering tensions in West Asia and a global unwinding of the AI-led rally. Track how sensex, Nifty fared on June 8.
The Indian pharma industry is estimated to grow at 9-11 per cent in 2021-22 and in the next few quarters, it will be driven by domestic and emerging markets, according to ratings agency ICRA. In a sample of 21 Indian pharmaceutical companies, ICRA said revenue growth was moderate at 6.4 per cent in the second quarter of FY22, down from 16 per cent in the first quarter of 2021-22. The normalisation of the base and pricing pressures in the US market were the major reasons for slowing growth momentum in Q2 FY22, even as growth under domestic and emerging markets remained healthy, ICRA said in a statement.
A top executive of Sigachi Industries has been arrested in connection with the explosion at its pharma plant in Telangana in June, which resulted in 54 deaths.
When compared to the domestic sales of April 2019, the growth is around 37 per cent. However, compared to the previous month (March), the growth is 18.4 per cent.
An Enforcement Directorate (ED) probe has revealed that the manufacturer of Coldrif syrup, linked to the deaths of at least 20 children in Madhya Pradesh, used industrial-grade raw materials without quality checks. The investigation also found that Tamil Nadu Drugs Control Department officials were in frequent contact with the company but failed to conduct mandated inspections.
